PA8801401A1 - Arilindenopirimidinas y su uso como adenosina a2a - Google Patents

Arilindenopirimidinas y su uso como adenosina a2a

Info

Publication number
PA8801401A1
PA8801401A1 PA20088801401A PA8801401A PA8801401A1 PA 8801401 A1 PA8801401 A1 PA 8801401A1 PA 20088801401 A PA20088801401 A PA 20088801401A PA 8801401 A PA8801401 A PA 8801401A PA 8801401 A1 PA8801401 A1 PA 8801401A1
Authority
PA
Panama
Prior art keywords
arylindenopirimidins
adenosine
therapèutic
profilàcyic
arilindenopirimidines
Prior art date
Application number
PA20088801401A
Other languages
English (en)
Inventor
C Shook Brian
F Jackson Paul
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PA8801401A1 publication Critical patent/PA8801401A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ESTA INVENCIÒN SE REFIERE A ARILINDENOPIRIMIDINAS NOVEDOSAS A, B Y C Y A SUS USOS TERAPÈUTICOS Y PROFILÀCYICOS. LOS TRASTORNOS QUE SE TRATAN O PREVIENEN UTILIZANDO ESTOSCOMPUESTOS INCLUYEN LA ENFERMEDAD DE PARKINSON.
PA20088801401A 2007-10-25 2008-10-22 Arilindenopirimidinas y su uso como adenosina a2a PA8801401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98245607P 2007-10-25 2007-10-25

Publications (1)

Publication Number Publication Date
PA8801401A1 true PA8801401A1 (es) 2009-05-15

Family

ID=40225283

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088801401A PA8801401A1 (es) 2007-10-25 2008-10-22 Arilindenopirimidinas y su uso como adenosina a2a

Country Status (13)

Country Link
US (1) US20090111804A1 (es)
EP (1) EP2220053B1 (es)
JP (1) JP2011500833A (es)
CN (1) CN101835760A (es)
AR (1) AR069026A1 (es)
AT (1) ATE509012T1 (es)
AU (1) AU2008316821A1 (es)
CL (1) CL2008003184A1 (es)
PA (1) PA8801401A1 (es)
PE (1) PE20091345A1 (es)
TW (1) TW200934496A (es)
UY (1) UY31421A1 (es)
WO (1) WO2009055548A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105540A1 (en) * 2009-10-29 2011-05-05 Jackson Paul F 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19627430A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
PT921125E (pt) * 1997-12-05 2002-06-28 Hoffmann La Roche Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
US20040127510A1 (en) * 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
DK1673354T3 (da) * 2003-10-03 2009-07-27 Ortho Mcneil Janssen Pharm Arylindenopyridiner og arylindenopyrimidiner og deres anvendelse som adenosin-A2a-receptorantagonister

Also Published As

Publication number Publication date
ATE509012T1 (de) 2011-05-15
CN101835760A (zh) 2010-09-15
JP2011500833A (ja) 2011-01-06
EP2220053B1 (en) 2011-05-11
WO2009055548A1 (en) 2009-04-30
EP2220053A1 (en) 2010-08-25
UY31421A1 (es) 2009-04-30
AU2008316821A1 (en) 2009-04-30
CL2008003184A1 (es) 2009-10-16
PE20091345A1 (es) 2009-09-24
AR069026A1 (es) 2009-12-23
US20090111804A1 (en) 2009-04-30
TW200934496A (en) 2009-08-16

Similar Documents

Publication Publication Date Title
NI201000005A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico.
ECSP099619A (es) Anticuerpos anti-robo4 y sus usos
BRPI0819191A2 (pt) uso de oligonucleotídeos com bases modificadas como agentes antivirais.
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
CR10149A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
CL2013002517A1 (es) Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
EA200900202A1 (ru) Селективные модуляторы андрогенного рецептора, их аналоги и производные и их использование
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
HN2006037713A (es) Compuestos utiles en terapia
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
ECSP10010095A (es) 2'-fluoro-2'-desoxitetrahidrouridinas como inhibidores de citidina desaminasa
ECSP088225A (es) 1h-imidazopiridinas sustituidas con hidroxi y procedimientos
ECSP066391A (es) [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
CL2009001476A1 (es) Compuestos derivados de 2,4-diamin-n2-fenil pirimidina sustituidos, mediadores de la inhibicion de igf-1r; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades autoinmune, por trasplante, infecciosas o un trastorno proliferativo celular.
HN2008000311A (es) Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
DK1866324T3 (da) Phosphoramidatderivater af nukleosidforbindelser til anvendelse i behandlingen af cancer
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina
UY29417A1 (es) Agentes endoparasiticidas
CO6321169A2 (es) Metilenaminas de tieno[2,3-d] pirimidina y su uso como antagonistas de receptores de adenosina a2a
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
UY31717A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas y su uso
BRPI0923740A2 (pt) "artigos absorventes descartáveis do tipo para vestir com sinais específicos de gênero".
PA8801501A1 (es) ARILINDENOPIRIMIDINAS Y SU USO COMO ANTAGONISTAS DEL RECEPTOR A 2a DE ADENOSINA